Troleandomycin
Appearance
(Redirected from Triacetyloleandomycin)
Clinical data | |
---|---|
AHFS/Drugs.com | Multum Consumer Information |
MedlinePlus | a604026 |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.018.539 |
Chemical and physical data | |
Formula | C41H67NO15 |
Molar mass | 813.979 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Troleandomycin (TAO for short[1]) is a macrolide antibiotic. It was sold in Italy (branded Triocetin) and Turkey (branded Tekmisin). It is no longer sold in Italy as of 2018.[citation needed]
The drug's mode of action is to bind to the ribosome, specifically in the tunnel through which the newly formed peptide egresses, thereby halting protein synthesis.[2] Troleandomycin is a CYP3A4 inhibitor that may cause drug interactions.[citation needed]
References
[edit]- ^ Zeiger RS, Schatz M, Sperling W, Simon RA, Stevenson DD (December 1980). "Efficacy of troleandomycin in outpatients with severe, corticosteroid-dependent asthma". The Journal of Allergy and Clinical Immunology. 66 (6): 438–46. doi:10.1016/0091-6749(80)90003-2. PMID 6968762.
- ^ Gürel G, Blaha G, Steitz TA, Moore PB (December 2009). "Structures of triacetyloleandomycin and mycalamide A bind to the large ribosomal subunit of Haloarcula marismortui". Antimicrobial Agents and Chemotherapy. 53 (12): 5010–4. doi:10.1128/AAC.00817-09. PMC 2786347. PMID 19738021.